Pinpoint Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Pinpoint Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$1.71M	Sell	3,532 -3,928	-53%	-$1.83M	0.3%	32
2024 Q4	$3M	Sell	7,460 -800	-10%	-$371K	0.53%	29
2024 Q3	$3.84M	Buy	8,260 +300	+4%	+$144K	0.82%	20
2024 Q2	$3.73M	Buy	7,960 +1,457	+22%	+$632K	0.53%	26
2024 Q1	$2.72M	Buy	+6,503	New	+$2.75M	0.44%	38

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Pinpoint Asset Management's VRTX Position: Q1 2025 in Review

Pinpoint Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 53% in Q1 2025, selling an estimated $1.83M and leaving 3,532 shares worth $1.71M. The position accounts for 0.3% of the portfolio, ranked #32.

Pinpoint Asset Management first reported a position in VRTX in Q1 2024 and has held it in 5 quarters since. The position peaked at $3.84M in Q3 2024. 1,612 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

Pinpoint Asset Management held 3,532 shares of Vertex Pharmaceuticals worth $1.71M as of Q1 2025.
Pinpoint Asset Management sold 3,928 Vertex Pharmaceuticals shares in Q1 2025, an estimated $1.83M.
Vertex Pharmaceuticals made up 0.3% of Pinpoint Asset Management's portfolio in Q1 2025, its #32 holding.
Pinpoint Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 5 quarters since.
Pinpoint Asset Management's Vertex Pharmaceuticals position peaked at $3.84M in Q3 2024.
1,612 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Pinpoint Asset Management's 13F filing for Q1 2025, filed 12 May 2025.